Clinical Pipeline

Product Candidates Program Area Preclinical Phase 1 Phase 2/3



Bowen's Disease/In situ carcinoma

Actinic Keratosis

Early Pipeline PT-001np

Severely UV-damaged skin

Male Pattern Baldness

  • Lead program, PT-001mn, to deliver p16-directed riCasp9 to keratinocytes in treated Bowen’s lesions using proprietary delivery technology
  • Early pipeline developing single, one time therapy for Male Pattern Baldness, in order to avoid systemic medications directed at this disease that have known, as well as newly discovered, serious side effects